<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653429</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1691</org_study_id>
    <nct_id>NCT03653429</nct_id>
  </id_info>
  <brief_title>Efficacy of Tranexamic Acid in Foot and Ankle Surgeries</brief_title>
  <official_title>Efficacy of Tranexamic Acid in Foot and Ankle Surgeries- a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiology of foot and ankle surgeries that present to the hospitals in the US are often
      underestimated. However there has been growing emphasis on identification of these injuries
      and practice patterns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% of all foot and ankle fractures are open. Excellent operative field without
      measurable bleeding remain prerequisite of most orthopedic procedures. Increase blood loss
      can increase the risk of infection, hematoma formation and wound complications. Presence of
      blood in synovium not only has direct corrosive effects but also causes increased intra
      capsular pressure leading to capsular fibrosis culminating as ankyloses.

      Tourniquets are employed to optimize surgical field visualization thereby limiting operative
      duration and improving technical precision. There are several unwanted effects that can arise
      from use of tourniquet like neurapraxia, vascular injury, post operative swelling etc. Hence
      there is a growing interest in achieving the same operative goals without the use of
      tourniquet.

      Antifibrinolytics come to one's rescue to achieve a blood sparing effect. Its efficacy in
      reducing intra operative and post operative blood loss is well documented in cardiac surgery,
      hip and knee replacement surgery and spinal surgery. Tranexamic acid is a synthetic
      antifibrinolytic drug that competitively blocks the lysine-binding sites of plasminogen,
      plasmin and tissue plasminogen activator, thereby delaying fibrinolysis and blood clot
      degradation. It has been effectively used as IV, oral, topical as well as intra articular
      dosing. The effects of IV administration lasts 8-17 hours after the initial dose. Orthopedic
      surgeons have incorporated TXA into multiple elective surgeries as a means of reducing blood
      loss and transfusion requirements. Reduced bleeding translates to decreased incidence of
      wound hematoma and other complications.

      Effectiveness of Tranexamic acid(TXA) is unknown in foot and ankle surgeries. The aim of this
      study is to not only evaluate effectiveness of intravenous TXA in reducing post operative
      blood loss during foot and ankle surgeries but also if it modulates to reduced wound
      complications and reduced narcotic consumption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Estimated Blood Loss</measure>
    <time_frame>Average intra operative time 1-2 hours</time_frame>
    <description>Total estimated blood loss in millilitres during the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Wound Complications</measure>
    <time_frame>at first post-operative visit, 2 weeks post surgery</time_frame>
    <description>Number of participants with wound complications at first post-operative visit and at 2 weeks post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra Operative Narcotic Consumption</measure>
    <time_frame>Average intra operative time 1-2 hours</time_frame>
    <description>Total intraoperative narcotic consumption in terms of morphine equivalents.(mme)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Narcotic Consumption</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>Post operative narcotic consumption, morphine mili equivalents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Foot and Ankle Surgeries</condition>
  <condition>Bunion</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg/kg intravenous tranexamic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10mg/kg intravenous normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>administered prior to surgical incision</description>
    <arm_group_label>Tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>administered prior to surgical incision</description>
    <arm_group_label>Normal Saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA (American Society of Anesthesiology) class I-IV

          -  age 8-75.

        Exclusion Criteria:

          -  ASA class V

          -  morbid obesity

          -  patient refusal

          -  patients with known coagulopathy disorder

          -  renal insufficiency

          -  hepatic dysfunction

          -  serious cardiac disease

          -  an allergy to TXA or receiving antiplatelet and /or anticoagulant drugs will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ettore Vulcano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ichan School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichan School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Xie B, Tian J, Zhou DP. Administration of Tranexamic Acid Reduces Postoperative Blood Loss in Calcaneal Fractures: A Randomized Controlled Trial. J Foot Ankle Surg. 2015 Nov-Dec;54(6):1106-10. doi: 10.1053/j.jfas.2015.07.006. Epub 2015 Aug 24.</citation>
    <PMID>26310621</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <results_first_submitted>December 31, 2019</results_first_submitted>
  <results_first_submitted_qc>April 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2020</results_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Yan Lai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>foot and ankle surgeries</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>wound healing</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bunion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03653429/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03653429/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid Group</title>
          <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline Group</title>
          <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid Group</title>
          <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline Group</title>
          <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.24" spread="15.49"/>
                    <measurement group_id="B2" value="52.51" spread="14.05"/>
                    <measurement group_id="B3" value="51.89" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Estimated Blood Loss</title>
        <description>Total estimated blood loss in millilitres during the surgery</description>
        <time_frame>Average intra operative time 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Group</title>
            <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Group</title>
            <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
          </group>
        </group_list>
        <measure>
          <title>Total Estimated Blood Loss</title>
          <description>Total estimated blood loss in millilitres during the surgery</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.41" spread="136.78"/>
                    <measurement group_id="O2" value="18.75" spread="49.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Wound Complications</title>
        <description>Number of participants with wound complications at first post-operative visit and at 2 weeks post surgery</description>
        <time_frame>at first post-operative visit, 2 weeks post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Group</title>
            <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Group</title>
            <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wound Complications</title>
          <description>Number of participants with wound complications at first post-operative visit and at 2 weeks post surgery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>first post-operative visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra Operative Narcotic Consumption</title>
        <description>Total intraoperative narcotic consumption in terms of morphine equivalents.(mme)</description>
        <time_frame>Average intra operative time 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Group</title>
            <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Group</title>
            <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
          </group>
        </group_list>
        <measure>
          <title>Intra Operative Narcotic Consumption</title>
          <description>Total intraoperative narcotic consumption in terms of morphine equivalents.(mme)</description>
          <units>MME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.37" spread="58.80"/>
                    <measurement group_id="O2" value="125.40" spread="79.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Narcotic Consumption</title>
        <description>Post operative narcotic consumption, morphine mili equivalents</description>
        <time_frame>2 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Group</title>
            <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Group</title>
            <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Narcotic Consumption</title>
          <description>Post operative narcotic consumption, morphine mili equivalents</description>
          <units>MME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="13.32"/>
                    <measurement group_id="O2" value="10.10" spread="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid Group</title>
          <description>10mg/kg intravenous tranexamic acid administered prior to surgical incision</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline Group</title>
          <description>10mg/kg intravenous normal saline administered prior to surgical incision</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Poonam Pai B. H</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-523-4000</phone>
      <email>poonam.paibantwalhebbalasankatte@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

